Saudi FDA approves Wegovy (semaglutide) for MASLD/MASH
- Saudi Arabia’s SFDA now lists Wegovy for noncirrhotic MASH with F2–F3 fibrosis, adding fatty liver disease to semaglutide’s Saudi label alongside obesity and CV risk. - The Saudi listing uses Wegovy 2.4 mg and mirrors the key liver-disease wording already used in the US, where 63% saw MASH resolution at 72 weeks. - Fatty liver is being treated more explicitly as a metabolic disease — not just a liver problem — which could widen reimbursement fights.
Wegovy just picked up a new role in Saudi Arabia — and it’s a meaningful one. The Saudi Food and Drug Authority’s drug database now shows semaglutide 2.4 mg approved not just for obesity and cardiovascular risk reduction, but also for noncirrhotic MASH in adults with moderate to advanced liver fibrosis. That matters because MASH is the dangerous inflammatory form of fatty liver disease, and it sits right at the intersection of obesity, diabetes, cardiometabolic risk, and liver damage. Basically, this is another sign that regulators are starting to treat fatty liver as part of the metabolic disease stack, not as a side issue. ### What exactly changed? The change is on the Saudi label. In the SFDA drug information entry for Wegovy, the listed uses now include “the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis,” specifically F2 to F3 fibrosis. The same Saudi entry also lists the older uses — weight management and reduction of major cardiovascular events in adults with known heart disease and overweight or obesity. (sdi.sfda.gov.sa) So this is not a new drug launch. It’s a label expansion inside Saudi Arabia for a high-profile GLP-1 already on the market there. ### Why is MASH a big deal? MASH is the aggressive form of metabolic-associated fatty liver disease. Fat builds up in the liver, inflammation kicks in, and then scarring follows. The scary part is that many people do not feel much until the liver is already in trouble. Once scarring progresses far enough, the path can lead to cirrhosis, liver failure, liver cancer, transplant, or death. That is why a drug that can move liver biopsy endpoints in the right direction gets so much attention — the disease burden is huge, but treatment options have been thin. (sdi.sfda.gov.sa) ### What kind of patients is this for? Not everyone with fatty liver. The label is narrower than that. It is for adults with noncirrhotic MASH and moderate to advanced fibrosis — stages F2 to F3. That means patients already have meaningful liver scarring, but have not yet crossed into cirrhosis. The label also keeps the standard lifestyle framing around Wegovy — reduced-calorie diet and increased physical activity stay part of the package. (fda.gov) ### What is the evidence behind it? The core evidence comes from the phase 3 ESSENCE program that supported the US approval. In the FDA’s summary of the interim 72-week analysis, 63% of patients on Wegovy had MASH resolution with no worsening of fibrosis, versus 34% on placebo. On the fibrosis endpoint, 37% on Wegovy improved liver scarring with no worsening of MASH, versus 22% on placebo. That is why this got through on an accelerated path in the US — the biopsy results were strong enough to justify earlier access while longer-term outcomes are still being confirmed. (sdi.sfda.gov.sa) ### Why does the cardiovascular angle matter? Because semaglutide is no longer being framed as only a weight-loss drug. NICE in the UK just published TA1152 on May 7, 2026, backing semaglutide for reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Put that next to obesity and now liver disease, and you get the real story — one molecule is being reimbursed and prescribed across multiple metabolic complications that used to live in separate silos. (fda.gov) ### Does this change the reimbursement fight? Very likely. A fatty-liver indication gives payers and health systems a different justification than “weight loss.” Liver fibrosis is a harder endpoint and a more obviously medical one. The catch is that MASH labeling is still tied to a defined subgroup, and some approvals rely on surrogate endpoints while confirmatory follow-up continues. But every added indication makes it easier for health systems to argue that semaglutide is preventing downstream costs, not just lowering weight. (nice.org.uk) ### Why Saudi Arabia specifically? Saudi Arabia has a heavy burden of obesity, diabetes, and related metabolic disease, so a MASH indication lands in a market where the overlap is not theoretical. The SFDA listing also shows Wegovy already established locally, with a registered 2.4 mg product from Novo Nordisk and a public price listed in riyals. So this is not just symbolic regulatory housekeeping — it plugs a new indication into an existing commercial and prescribing setup. (fda.gov) ### Bottom line? This is a liver-drug story on the surface, but really it’s a metabolic-disease story. Saudi Arabia’s label update says Wegovy now spans obesity, cardiovascular risk, and MASH in one market. That is the bigger shift — fatty liver is moving out of the margins and into the main GLP-1 treatment map. (sdi.sfda.gov.sa)
